- Home
- CRGY vs CELC Comparison
CRGY vs CELC Comparison
Compare CRGY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRGY | CELC |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRGY | CELC |
|---|---|---|
| Price | $12.74 | $117.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $14.36 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 8.3M | 660.8K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,579,782,000.00 | N/A |
| Revenue This Year | $29.90 | N/A |
| Revenue Next Year | N/A | $740.70 |
| P/E Ratio | $99.08 | ★ N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $7.68 | $9.02 |
| 52 Week High | $14.02 | $124.41 |
Technical Indicators
Market Signals| Indicator | CRGY | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 53.88 |
| Support Level | $8.29 | $99.38 |
| Resistance Level | $14.02 | $117.61 |
| Average True Range (ATR) | 0.57 | 6.22 |
| MACD | -0.15 | 0.90 |
| Stochastic Oscillator | 41.80 | 65.01 |
Price Performance
Historical ComparisonAbout CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.